SCHEMBL14836330

SCHEMBL14836330

CCCS(=O)(=O)N1CCN(C2(CNC(=O)c3c(N)cccc3Cl)CCCCCC2)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
SLC6A9 P48067 20/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16497093 1.00 SLC6A9 (1.00) SLC6A9
Hydrochloric Acid SCHEMBL16497368 0.99 SLC6A9 (1.00) SLC6A9
Hydrochloric Acid SCHEMBL16496737 0.99 SLC6A9 (1.00) SLC6A9
SCHEMBL14837014 0.99 SLC6A9 (1.00) SLC6A9
Hydrochloric Acid SCHEMBL16496893 0.98 SLC6A9 (0.98) SLC6A9
SCHEMBL14836365 0.97 SLC6A9 (1.00) SLC6A9
Hydrochloric Acid SCHEMBL16496320 0.96 SLC6A9 (0.98) SLC6A9
SCHEMBL14836559 0.94 SLC6A9 (1.00) SLC6A9
Hydrochloric Acid SCHEMBL16496290 0.94 SLC6A9 (1.00) SLC6A9
SCHEMBL14836463 0.93 SLC6A9 (1.00) SLC6A9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2575815-A1 GLYCINE TRANSPORTER-1 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF Albany Molecular Research, Inc. (US) 2013-04-10 EP claimed
US-20110312931-A1 GLYCINE TRANSPORTER-1 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF ALBANY MOLECULAR RESEARCH, INC. (US) 2011-12-22 US claimed
WO-2011153359-A1 GLYCINE TRANSPORTER-1 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF ALBANY MOLECULAR RESEARCH, INC. (US) 2011-12-08 WO claimed
US-9045445-B2 Glycine transporter-1 inhibitors, methods of making them, and uses thereof ALBANY MOLECULAR RESEARCH, INC. (US) 2015-06-02 US disclosed
US-9045445-B2 Glycine transporter-1 inhibitors, methods of making them, and uses thereof ALBANY MOLECULAR RESEARCH, INC. (US) 2015-06-02 US disclosed
EP-2575815-A1 GLYCINE TRANSPORTER-1 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF Albany Molecular Research, Inc. (US) 2013-04-10 EP disclosed
US-20110312931-A1 GLYCINE TRANSPORTER-1 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF ALBANY MOLECULAR RESEARCH, INC. (US) 2011-12-22 US disclosed
US-20110312931-A1 GLYCINE TRANSPORTER-1 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF ALBANY MOLECULAR RESEARCH, INC. (US) 2011-12-22 US disclosed
WO-2011153359-A1 GLYCINE TRANSPORTER-1 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF ALBANY MOLECULAR RESEARCH, INC. (US) 2011-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110312931-A1 GLYCINE TRANSPORTER-1 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF SLC6A5, SLC7A1, AGXT SLC6A9 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.